BACKGROUND The purpose of this study was to evaluate the efficacy and duration of action of once-daily dosing with alcaftadine 0.25% ophthalmic solution and olopatadine 0.2% ophthalmic solution as compared with placebo in the prevention of ocular itching, and to directly compare the efficacy of alcaftadine 0.25% with olopatadine 0.2% in the prevention of ocular itching associated with allergic ...

Fifty-one patients with raised intraocular pressure (IOP) were treated for up to four years with one of three ophthalmic solutions: 0.5% levobunolol, 1% levobunolol, or 0.5% timolol. The study was conducted as a double-masked, randomised trial in which medications were administered twice daily to both eyes. Levobunolol and timolol were equally effective in reducing overall mean IOP; reductions ...

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information --------------WARNINGS AND PRECAUTIONS-----------­ needed to use QOLIANA® (brimonidine tartrate • Potentiation of vascular insufficiency (5.1). ophthalmic solution), 0.15% safely and effectively. See full prescribing information for QOLIANA® --------------------ADVERSE REACTIONS-------------------(brimonid...

A simple and rapid calorimetric method for the determination of 10 sulphonamides as single entities and sulphamethoxazole in combination with trimethoprim without prior separation was developed. The method is based on the reaction of sulphonamide with phenothiazine and N-bromosuccinimide at pH 6 to produce a blue coloured product after acidification. The chromogen for all the sulphonamides was ...

PURPOSE We clarified the effects of an ophthalmic solution of a peroxisome proliferator-activated receptor gamma (PPARγ) agonist on corneal inflammation and wound healing after alkali burn injury in rats. METHODS After alkali exposure, either an ophthalmic solution with 0.1% pioglitazone hydrochloride (the PPARγ group) or vehicle (the vehicle group) was topically applied to the cornea until d...

BACKGROUND Bimatoprost ophthalmic solution 0·03% is approved in several countries for the treatment of eyelash hypotrichosis. Previous trials were limited to 4 months of treatment and primarily idiopathic hypotrichosis. OBJECTIVES To evaluate the long-term safety and efficacy of bimatoprost in patients with idiopathic or chemotherapy-induced hypotrichosis. METHODS This multicentre, double-m...